Age, JAK2 V617F and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis

Leukemia

Volumn 27, Issue 9, 2013, Pages 1826-1831

  Broseus J ^a   Alpermann, T ^b   Wulfert, M ^c   Florensa Brichs, L ^d   Jeromin, S ^b   Lippert, E ^e   Rozman, M ^f   Lifermann, F ^g   Grossmann, V ^b   Haferlach, T ^b   Germing, U ^c   Luno E ^h   Girodon, F ⁱ   Schnittger, S ^b  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

^b MLL MUNICH LEUKEMIA LABORATORY   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d HOSPITAL DEL MAR   (Spain)

^e University Hospital   (France)

^f HOSPITAL CLÍNIC   (Spain)

^g Dax Hospital   (France)

^h Servicio de Salud del Principado de Asturias   (Spain)

ⁱ DIJON UNIVERSITY HOSPITAL   (France)

Author keywords

prognostic impact; refractory anaemia with ring sideroblasts and marked thrombocytosis; SF3B1; survival

Indexed keywords

JANUS KINASE 2; PROTEIN; SPLICING FACTOR 3B SUBUNIT 1; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ARTICLE; DISEASE CLASSIFICATION; FEMALE; FOLLOW UP; GENE MUTATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; RNA SPLICING; SURVIVAL; THROMBOCYTE COUNT; THROMBOCYTOSIS; WORLD HEALTH ORGANIZATION;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANEMIA, REFRACTORY; ANEMIA, SIDEROBLASTIC; CHROMOSOME MAPPING; FEMALE; HUMANS; JANUS KINASE 2; KARYOTYPE; MALE; MIDDLE AGED; MUTATION; MUTATION RATE; PHOSPHOPROTEINS; PROGNOSIS; RIBONUCLEOPROTEIN, U2 SMALL NUCLEAR; THROMBOCYTOSIS; YOUNG ADULT;

EID: 84883741044     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.120     Document Type: Article

References (39)

1. Vardiman JW, Bennett JM, Bain BJ, Baumann I, Thiele J, Orazi A. Myelodysplastic/myeloproliferative neoplasms, unclassifiable. In: Swerdlow SH, Campo E, Lee Harris N, Jaffe ES, Pileri SA, Stein H et al. (eds) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue. 4th edn. IARC: Lyon, France, 2008, pp 85-86.
2. Hasserjian RP, Gatterman N, Bennett JM, Brunning RD, Thiele J. Refractory anemia with ringed sideroblasts. In: Swerdlow SH, Campo E, Lee Harris N, Jaffe ES, Pileri SA, Stein H et al. (eds) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue. 4th edn. IARC: Lyon, France, 2008, pp 96-97.
3. Thiele J, Kvasnicka HM, Orazi A, Tefferi A, Gisslinger H. Essential thrombocythaemia. In: Swerdlow SH, Campo E, Lee Harris N, Jaffe ES, Pileri SA, Stein H et al. (eds) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue. 4th edn. IARC: Lyon, France, 2008, pp 48-50.
4. Ceesay MM, Lea NC, Ingram W, Westwood NB, Gaken J, Mohamedali A et al. The JAK2 V617F mutation is rare in RARS but common in RARS-T. Leukemia 2006; 20: 2060-2061. (Pubitemid 44614905)
5. Boissinot M, Garand R, Hamidou M, Hermouet S. The JAK2-V617F mutation and essential thrombocythemia features in a subset of patients with refractory anemia with ring sideroblasts (RARS). Blood 2006; 108: 1781-1782. (Pubitemid 44316158)
6. Flach J, Dicker F, Schnittger S, Kohlmann A, Haferlach T, Haferlach C. Mutations of JAK2 and TET2, but not CBL are detectable in a high portion of patients with refractory anemia with ring sideroblasts and thrombocytosis. Haematologica 2010; 95: 518-519.
7. Gattermann N, Billiet J, Kronenwett R, Zipperer E, Germing U, Nollet F et al. High frequency of the JAK2 V617F mutation in patients with thrombocytosis (platelet count4600109/L) and ringed sideroblasts more than 15% considered as MDS/MPD, unclassifiable. Blood 2007; 109: 1334-1335. (Pubitemid 46220688)
8. Hellstrom-Lindberg E, Cazzola M. The role of JAK2 mutations in RARS and other MDS. Hematology Am Soc Hematol Educ Program 2008; 52-59.
9. Raya JM, Arenillas L, Domingo A, Bellosillo B, Gutierrez G, Luno E et al. Refractory anemia with ringed sideroblasts associated with thrombocytosis: comparative analysis of marked with non-marked thrombocytosis, and relationship with JAK2 V617F mutational status. Int J Hematol 2008; 88: 387-395.
10. Remacha AF, Nomdedeu JF, Puget G, Estivill C, Sarda MP, Canals C et al. Occurrence of the JAK2 V617F mutation in the WHO provisional entity: myelodysplastic/myeloproliferative disease, unclassifiable-refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Haematologica 2006; 91: 719-720. (Pubitemid 43799483)
11. Renneville A, Quesnel B, Charpentier A, Terriou L, Crinquette A, Lai JL et al. High occurrence of JAK2 V617 mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Leukemia 2006; 20: 2067-2070.
12. Schmitt-Graeff AH, Teo SS, Olschewski M, Schaub F, Haxelmans S, Kirn A et al. JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Haematologica 2008; 93: 34-40. (Pubitemid 351156149)
13. Szpurka H, Tiu R, Murugesan G, Aboudola S, Hsi ED, Theil KS et al. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation. Blood 2006; 108: 2173-2181. (Pubitemid 44497497)
14. Steensma DP, Tefferi A. JAK2 V617F and ringed sideroblasts: not necessarily RARS-T. Blood 2008; 111: 1748. (Pubitemid 351213476)
15. Wang SA, Hasserjian RP, Loew JM, Sechman EV, Jones D, Hao S et al. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis harbors JAK2 mutation and shows overlapping myeloproliferative and myelodysplastic features. Leukemia 2006; 20: 1641-1644. (Pubitemid 44264118)
16. Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006; 108: 3472-3476.
17. Schnittger S, Bacher U, Haferlach C, Dengler R, Krober A, Kern W et al. Detection of an MPLW515 mutation in a case with features of both essential thrombocythemia and refractory anemia with ringed sideroblasts and thrombocytosis. Leukemia 2008; 22: 453-455. (Pubitemid 351265131)
18. Wardrop D, Steensma DP. Is refractory anaemia with ring sideroblasts and thrombocytosis (RARS-T) a necessary or useful diagnostic category? Br J Haematol 2009; 144: 809-817.
19. Malcovati L, Della Porta MG, Pietra D, Boveri E, Pellagatti A, Galli A et al. Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Blood 2009; 114: 3538-3545.
20. Broseus J, Florensa L, Zipperer E, Schnittger S, Malcovati L, Richebourg S et al. Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis. Haematologica 2012; 97: 1036-1041.
21. Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011; 478: 64-69.
22. Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med 2011; 365: 1384-1395.
23. Visconte V, Makishima H, Jankowska A, Szpurka H, Traina F, Jerez A et al. SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts. Leukemia 2012; 26: 542-545.
24. Malcovati L, Papaemmanuil E, Bowen DT, Boultwood J, Della Porta MG, Pascutto C et al. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood 2011; 118: 6239-6246.
25. Damm F, Thol F, Kosmider O, Kade S, Loffeld P, Dreyfus F et al. SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications. Leukemia 2012; 26: 1137-1140.
26. Damm F, Kosmider O, Gelsi-Boyer V, Renneville A, Carbuccia N, Hidalgo-Curtis C et al. Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. Blood 2012; 119: 3211-3218.
27. Patnaik MM, Lasho TL, Hodnefield JM, Knudson RA, Ketterling RP, Garcia-Manero G et al. SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood 2012; 119: 569-572.
28. Visconte V, Makishima H, Maciejewski JP, Tiu RV. Emerging roles of the spliceosomal machinery in myelodysplastic syndromes and other hematological disorders. Leukemia 2012; 26: 2447-2454.
29. Visconte V, Rogers HJ, Singh J, Barnard J, Bupathi M, Traina F et al. SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes. Blood 2012; 120: 3173-3186.
30. Jeromin S, Haferlach T, Grossmann V, Alpermann T, Kowarsch A, Haferlach C et al. High frequencies of SF3B1 and JAK2 mutations in refractory anemia with ring sideroblasts associated with marked thrombocytosis strengthen the assignment to the category of myelodysplastic/myeloproliferative neoplasms. Haematologica 2013; 98: 15-17.
31. Cazzola M, Rossi M, Malcovati L. Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms. Blood 2013; 121: 260-269.
32. Lippert E, Boissinot M, Kralovics R, Girodon F, Dobo I, Praloran V et al. The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood 2006; 108: 1865-1867. (Pubitemid 44394995)
33. Schnittger S, Bacher U, Kern W, Schroder M, Haferlach T, Schoch C. Report on two novel nucleotide exchanges in the JAK2 pseudokinase domain: D620E and E627E. Leukemia 2006; 20: 2195-2197. (Pubitemid 44782853)
34. Schnittger S, Bacher U, Haferlach C, Geer T, Muller P, Mittermuller J et al. Detection of JAK2 exon 12 mutations in 15 patients with JAK2V617F negative polycythemia vera. Haematologica 2009; 94: 414-418.
35. Schnittger S, Bacher U, Haferlach C, Beelen D, Bojko P, Burkle D et al. Characterization of 35 new cases with four different MPLW515 mutations and essential thrombocytosis or primary myelofibrosis. Haematologica 2009; 94: 141-144.
36. Thol F, Kade S, Schlarmann C, Loffeld P, Morgan M, Krauter J et al. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood 2012; 119: 3578-3584.
37. Rymond B. Targeting the spliceosome. Nat Chem Biol. 2007; 3: 533-535. (Pubitemid 47294407)
38. Webb TR, Joyner AS, Potter PM. The development and application of small molecule modulators of SF3b as therapeutic agents for cancer. Drug Discov Today 2013; 18: 43-49.
39. Matsuda K, Ishida F, Ito T, Nakazawa H, Miura S, Taira C et al. Spliceosome-related gene mutations in myelodysplastic syndrome can be used as stable markers for monitoring minimal residual disease during follow-up. Leuk Res 2012; 36: 1393-1397.